nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—osteoarthritis—Prednisone—multiple sclerosis	0.254	0.5	CpDpCtD
Meloxicam—osteoarthritis—Methylprednisolone—multiple sclerosis	0.254	0.5	CpDpCtD
Meloxicam—PGD—Methotrexate—multiple sclerosis	0.118	0.327	CbGbCtD
Meloxicam—PTGS2—Triamcinolone—multiple sclerosis	0.0477	0.132	CbGbCtD
Meloxicam—PTGS2—Betamethasone—multiple sclerosis	0.0409	0.113	CbGbCtD
Meloxicam—ABCC4—Methotrexate—multiple sclerosis	0.0326	0.0901	CbGbCtD
Meloxicam—PTGS2—Dexamethasone—multiple sclerosis	0.0238	0.0659	CbGbCtD
Meloxicam—CYP3A4—Fingolimod—multiple sclerosis	0.0193	0.0535	CbGbCtD
Meloxicam—CYP3A4—Methylprednisolone—multiple sclerosis	0.0124	0.0344	CbGbCtD
Meloxicam—CYP2C8—Dexamethasone—multiple sclerosis	0.0116	0.0321	CbGbCtD
Meloxicam—CYP3A4—Triamcinolone—multiple sclerosis	0.00943	0.0261	CbGbCtD
Meloxicam—CYP3A4—Mitoxantrone—multiple sclerosis	0.00908	0.0251	CbGbCtD
Meloxicam—CYP2C9—Dexamethasone—multiple sclerosis	0.00809	0.0224	CbGbCtD
Meloxicam—CYP3A4—Betamethasone—multiple sclerosis	0.00809	0.0224	CbGbCtD
Meloxicam—CYP3A4—Prednisolone—multiple sclerosis	0.00798	0.0221	CbGbCtD
Meloxicam—CYP3A4—Prednisone—multiple sclerosis	0.00754	0.0209	CbGbCtD
Meloxicam—CYP3A4—Dexamethasone—multiple sclerosis	0.00471	0.013	CbGbCtD
Meloxicam—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000429	0.159	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000422	0.156	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000422	0.156	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000412	0.153	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000259	0.0958	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000255	0.0943	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000255	0.0943	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000249	0.0921	CbGdCrCtD
Meloxicam—CYP2C8—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000154	0.0118	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—multiple sclerosis	0.000132	0.0101	CbGpPWpGaD
Meloxicam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000132	0.0101	CbGpPWpGaD
Meloxicam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000132	0.0101	CbGpPWpGaD
Meloxicam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000127	0.00976	CbGpPWpGaD
Meloxicam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000127	0.00976	CbGpPWpGaD
Meloxicam—CYP2C8—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000126	0.00973	CbGpPWpGaD
Meloxicam—CYP2C8—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000126	0.00973	CbGpPWpGaD
Meloxicam—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000125	0.00964	CbGpPWpGaD
Meloxicam—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000125	0.00964	CbGpPWpGaD
Meloxicam—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000117	0.00898	CbGpPWpGaD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—multiple sclerosis	0.000109	0.0084	CbGpPWpGaD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—multiple sclerosis	0.000106	0.00817	CbGpPWpGaD
Meloxicam—PTGS1—Biological oxidations—CYP24A1—multiple sclerosis	0.000104	0.008	CbGpPWpGaD
Meloxicam—PTGS1—Biological oxidations—CYP27B1—multiple sclerosis	0.000104	0.008	CbGpPWpGaD
Meloxicam—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000103	0.00792	CbGpPWpGaD
Meloxicam—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000103	0.00792	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	9.84e-05	0.00757	CbGpPWpGaD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—multiple sclerosis	9.73e-05	0.00748	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—MBP—multiple sclerosis	9.49e-05	0.0073	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—multiple sclerosis	9.08e-05	0.00698	CbGpPWpGaD
Meloxicam—PGD—Metabolism—SRM—multiple sclerosis	9e-05	0.00692	CbGpPWpGaD
Meloxicam—Loss of consciousness—Betamethasone—multiple sclerosis	8.44e-05	0.000729	CcSEcCtD
Meloxicam—Hypersensitivity—Mitoxantrone—multiple sclerosis	8.44e-05	0.000728	CcSEcCtD
Meloxicam—Paraesthesia—Prednisolone—multiple sclerosis	8.44e-05	0.000728	CcSEcCtD
Meloxicam—Tachycardia—Triamcinolone—multiple sclerosis	8.43e-05	0.000728	CcSEcCtD
Meloxicam—Mental disorder—Prednisone—multiple sclerosis	8.42e-05	0.000727	CcSEcCtD
Meloxicam—Nausea—Azathioprine—multiple sclerosis	8.41e-05	0.000726	CcSEcCtD
Meloxicam—Tachycardia—Methylprednisolone—multiple sclerosis	8.41e-05	0.000726	CcSEcCtD
Meloxicam—Skin disorder—Methylprednisolone—multiple sclerosis	8.37e-05	0.000723	CcSEcCtD
Meloxicam—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	8.37e-05	0.00644	CbGpPWpGaD
Meloxicam—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	8.37e-05	0.00644	CbGpPWpGaD
Meloxicam—Malnutrition—Prednisone—multiple sclerosis	8.37e-05	0.000722	CcSEcCtD
Meloxicam—Erythema—Prednisone—multiple sclerosis	8.37e-05	0.000722	CcSEcCtD
Meloxicam—Hyperhidrosis—Triamcinolone—multiple sclerosis	8.35e-05	0.000721	CcSEcCtD
Meloxicam—Agranulocytosis—Methotrexate—multiple sclerosis	8.35e-05	0.000721	CcSEcCtD
Meloxicam—Hyperhidrosis—Methylprednisolone—multiple sclerosis	8.33e-05	0.000719	CcSEcCtD
Meloxicam—Convulsion—Dexamethasone—multiple sclerosis	8.32e-05	0.000718	CcSEcCtD
Meloxicam—Convulsion—Betamethasone—multiple sclerosis	8.32e-05	0.000718	CcSEcCtD
Meloxicam—Hypertension—Betamethasone—multiple sclerosis	8.29e-05	0.000716	CcSEcCtD
Meloxicam—Hypertension—Dexamethasone—multiple sclerosis	8.29e-05	0.000716	CcSEcCtD
Meloxicam—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	8.26e-05	0.00635	CbGpPWpGaD
Meloxicam—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	8.26e-05	0.00635	CbGpPWpGaD
Meloxicam—Asthenia—Mitoxantrone—multiple sclerosis	8.22e-05	0.000709	CcSEcCtD
Meloxicam—ABCC4—Hemostasis—MERTK—multiple sclerosis	8.21e-05	0.00632	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—CD58—multiple sclerosis	8.21e-05	0.00632	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—SELPLG—multiple sclerosis	8.21e-05	0.00632	CbGpPWpGaD
Meloxicam—Myalgia—Dexamethasone—multiple sclerosis	8.18e-05	0.000706	CcSEcCtD
Meloxicam—Myalgia—Betamethasone—multiple sclerosis	8.18e-05	0.000706	CcSEcCtD
Meloxicam—Anxiety—Dexamethasone—multiple sclerosis	8.15e-05	0.000703	CcSEcCtD
Meloxicam—Anxiety—Betamethasone—multiple sclerosis	8.15e-05	0.000703	CcSEcCtD
Meloxicam—Discomfort—Dexamethasone—multiple sclerosis	8.08e-05	0.000697	CcSEcCtD
Meloxicam—Discomfort—Betamethasone—multiple sclerosis	8.08e-05	0.000697	CcSEcCtD
Meloxicam—Haemoglobin—Methotrexate—multiple sclerosis	8.07e-05	0.000697	CcSEcCtD
Meloxicam—Hypotension—Methylprednisolone—multiple sclerosis	8.06e-05	0.000695	CcSEcCtD
Meloxicam—Pain—Prednisolone—multiple sclerosis	8.03e-05	0.000693	CcSEcCtD
Meloxicam—Haemorrhage—Methotrexate—multiple sclerosis	8.03e-05	0.000693	CcSEcCtD
Meloxicam—Hepatitis—Methotrexate—multiple sclerosis	8.03e-05	0.000693	CcSEcCtD
Meloxicam—Pharyngitis—Methotrexate—multiple sclerosis	7.97e-05	0.000688	CcSEcCtD
Meloxicam—Urinary tract disorder—Methotrexate—multiple sclerosis	7.93e-05	0.000684	CcSEcCtD
Meloxicam—Vision blurred—Prednisone—multiple sclerosis	7.88e-05	0.00068	CcSEcCtD
Meloxicam—Urethral disorder—Methotrexate—multiple sclerosis	7.87e-05	0.000679	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	7.87e-05	0.000679	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	7.85e-05	0.000678	CcSEcCtD
Meloxicam—Oedema—Dexamethasone—multiple sclerosis	7.84e-05	0.000677	CcSEcCtD
Meloxicam—Anaphylactic shock—Betamethasone—multiple sclerosis	7.84e-05	0.000677	CcSEcCtD
Meloxicam—Anaphylactic shock—Dexamethasone—multiple sclerosis	7.84e-05	0.000677	CcSEcCtD
Meloxicam—Oedema—Betamethasone—multiple sclerosis	7.84e-05	0.000677	CcSEcCtD
Meloxicam—Diarrhoea—Mitoxantrone—multiple sclerosis	7.84e-05	0.000676	CcSEcCtD
Meloxicam—Insomnia—Triamcinolone—multiple sclerosis	7.81e-05	0.000674	CcSEcCtD
Meloxicam—Insomnia—Methylprednisolone—multiple sclerosis	7.8e-05	0.000673	CcSEcCtD
Meloxicam—Infection—Dexamethasone—multiple sclerosis	7.79e-05	0.000672	CcSEcCtD
Meloxicam—Infection—Betamethasone—multiple sclerosis	7.79e-05	0.000672	CcSEcCtD
Meloxicam—Ill-defined disorder—Prednisone—multiple sclerosis	7.76e-05	0.00067	CcSEcCtD
Meloxicam—Paraesthesia—Triamcinolone—multiple sclerosis	7.76e-05	0.00067	CcSEcCtD
Meloxicam—Feeling abnormal—Prednisolone—multiple sclerosis	7.74e-05	0.000668	CcSEcCtD
Meloxicam—Paraesthesia—Methylprednisolone—multiple sclerosis	7.74e-05	0.000668	CcSEcCtD
Meloxicam—Visual impairment—Methotrexate—multiple sclerosis	7.74e-05	0.000668	CcSEcCtD
Meloxicam—Anaemia—Prednisone—multiple sclerosis	7.73e-05	0.000667	CcSEcCtD
Meloxicam—Shock—Betamethasone—multiple sclerosis	7.71e-05	0.000666	CcSEcCtD
Meloxicam—Shock—Dexamethasone—multiple sclerosis	7.71e-05	0.000666	CcSEcCtD
Meloxicam—Dyspnoea—Triamcinolone—multiple sclerosis	7.7e-05	0.000665	CcSEcCtD
Meloxicam—Nervous system disorder—Dexamethasone—multiple sclerosis	7.69e-05	0.000664	CcSEcCtD
Meloxicam—Nervous system disorder—Betamethasone—multiple sclerosis	7.69e-05	0.000664	CcSEcCtD
Meloxicam—Thrombocytopenia—Dexamethasone—multiple sclerosis	7.68e-05	0.000662	CcSEcCtD
Meloxicam—Thrombocytopenia—Betamethasone—multiple sclerosis	7.68e-05	0.000662	CcSEcCtD
Meloxicam—Tachycardia—Betamethasone—multiple sclerosis	7.65e-05	0.00066	CcSEcCtD
Meloxicam—Tachycardia—Dexamethasone—multiple sclerosis	7.65e-05	0.00066	CcSEcCtD
Meloxicam—Angioedema—Prednisone—multiple sclerosis	7.64e-05	0.00066	CcSEcCtD
Meloxicam—Dyspepsia—Triamcinolone—multiple sclerosis	7.61e-05	0.000656	CcSEcCtD
Meloxicam—Erythema multiforme—Methotrexate—multiple sclerosis	7.59e-05	0.000655	CcSEcCtD
Meloxicam—Dyspepsia—Methylprednisolone—multiple sclerosis	7.59e-05	0.000655	CcSEcCtD
Meloxicam—Hyperhidrosis—Betamethasone—multiple sclerosis	7.58e-05	0.000654	CcSEcCtD
Meloxicam—Hyperhidrosis—Dexamethasone—multiple sclerosis	7.58e-05	0.000654	CcSEcCtD
Meloxicam—Malaise—Prednisone—multiple sclerosis	7.54e-05	0.000651	CcSEcCtD
Meloxicam—Vertigo—Prednisone—multiple sclerosis	7.52e-05	0.000649	CcSEcCtD
Meloxicam—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	7.51e-05	0.00578	CbGpPWpGaD
Meloxicam—Eye disorder—Methotrexate—multiple sclerosis	7.51e-05	0.000648	CcSEcCtD
Meloxicam—Syncope—Prednisone—multiple sclerosis	7.5e-05	0.000647	CcSEcCtD
Meloxicam—Tinnitus—Methotrexate—multiple sclerosis	7.49e-05	0.000646	CcSEcCtD
Meloxicam—Urticaria—Prednisolone—multiple sclerosis	7.46e-05	0.000644	CcSEcCtD
Meloxicam—Cardiac disorder—Methotrexate—multiple sclerosis	7.45e-05	0.000643	CcSEcCtD
Meloxicam—Fatigue—Triamcinolone—multiple sclerosis	7.45e-05	0.000643	CcSEcCtD
Meloxicam—Fatigue—Methylprednisolone—multiple sclerosis	7.43e-05	0.000641	CcSEcCtD
Meloxicam—Pain—Triamcinolone—multiple sclerosis	7.39e-05	0.000638	CcSEcCtD
Meloxicam—Loss of consciousness—Prednisone—multiple sclerosis	7.35e-05	0.000635	CcSEcCtD
Meloxicam—PTGS1—Overview of nanoparticle effects—TNF—multiple sclerosis	7.34e-05	0.00564	CbGpPWpGaD
Meloxicam—Hypotension—Dexamethasone—multiple sclerosis	7.33e-05	0.000632	CcSEcCtD
Meloxicam—Hypotension—Betamethasone—multiple sclerosis	7.33e-05	0.000632	CcSEcCtD
Meloxicam—Angiopathy—Methotrexate—multiple sclerosis	7.29e-05	0.000629	CcSEcCtD
Meloxicam—Vomiting—Mitoxantrone—multiple sclerosis	7.28e-05	0.000628	CcSEcCtD
Meloxicam—Immune system disorder—Methotrexate—multiple sclerosis	7.25e-05	0.000626	CcSEcCtD
Meloxicam—Convulsion—Prednisone—multiple sclerosis	7.25e-05	0.000626	CcSEcCtD
Meloxicam—Mediastinal disorder—Methotrexate—multiple sclerosis	7.24e-05	0.000625	CcSEcCtD
Meloxicam—Hypertension—Prednisone—multiple sclerosis	7.22e-05	0.000623	CcSEcCtD
Meloxicam—Rash—Mitoxantrone—multiple sclerosis	7.22e-05	0.000623	CcSEcCtD
Meloxicam—Dermatitis—Mitoxantrone—multiple sclerosis	7.21e-05	0.000623	CcSEcCtD
Meloxicam—PTGS2—Spinal Cord Injury—AQP4—multiple sclerosis	7.19e-05	0.00553	CbGpPWpGaD
Meloxicam—Headache—Mitoxantrone—multiple sclerosis	7.17e-05	0.000619	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	7.14e-05	0.000616	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	7.14e-05	0.000616	CcSEcCtD
Meloxicam—Myalgia—Prednisone—multiple sclerosis	7.12e-05	0.000615	CcSEcCtD
Meloxicam—Arthralgia—Prednisone—multiple sclerosis	7.12e-05	0.000615	CcSEcCtD
Meloxicam—Feeling abnormal—Triamcinolone—multiple sclerosis	7.12e-05	0.000614	CcSEcCtD
Meloxicam—Feeling abnormal—Methylprednisolone—multiple sclerosis	7.1e-05	0.000613	CcSEcCtD
Meloxicam—Anxiety—Prednisone—multiple sclerosis	7.1e-05	0.000613	CcSEcCtD
Meloxicam—Alopecia—Methotrexate—multiple sclerosis	7.1e-05	0.000612	CcSEcCtD
Meloxicam—Insomnia—Betamethasone—multiple sclerosis	7.09e-05	0.000612	CcSEcCtD
Meloxicam—Insomnia—Dexamethasone—multiple sclerosis	7.09e-05	0.000612	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	7.07e-05	0.00061	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—multiple sclerosis	7.06e-05	0.00543	CbGpPWpGaD
Meloxicam—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	7.05e-05	0.000608	CcSEcCtD
Meloxicam—Paraesthesia—Dexamethasone—multiple sclerosis	7.04e-05	0.000608	CcSEcCtD
Meloxicam—Paraesthesia—Betamethasone—multiple sclerosis	7.04e-05	0.000608	CcSEcCtD
Meloxicam—Discomfort—Prednisone—multiple sclerosis	7.04e-05	0.000607	CcSEcCtD
Meloxicam—Mental disorder—Methotrexate—multiple sclerosis	7.04e-05	0.000607	CcSEcCtD
Meloxicam—Erythema—Methotrexate—multiple sclerosis	6.99e-05	0.000603	CcSEcCtD
Meloxicam—Malnutrition—Methotrexate—multiple sclerosis	6.99e-05	0.000603	CcSEcCtD
Meloxicam—PGD—Disease—GPC5—multiple sclerosis	6.92e-05	0.00533	CbGpPWpGaD
Meloxicam—Hypersensitivity—Prednisolone—multiple sclerosis	6.92e-05	0.000597	CcSEcCtD
Meloxicam—Dyspepsia—Betamethasone—multiple sclerosis	6.9e-05	0.000596	CcSEcCtD
Meloxicam—Dyspepsia—Dexamethasone—multiple sclerosis	6.9e-05	0.000596	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—multiple sclerosis	6.87e-05	0.00528	CbGpPWpGaD
Meloxicam—Urticaria—Triamcinolone—multiple sclerosis	6.86e-05	0.000592	CcSEcCtD
Meloxicam—Urticaria—Methylprednisolone—multiple sclerosis	6.85e-05	0.000591	CcSEcCtD
Meloxicam—Dysgeusia—Methotrexate—multiple sclerosis	6.85e-05	0.000591	CcSEcCtD
Meloxicam—Body temperature increased—Triamcinolone—multiple sclerosis	6.83e-05	0.000589	CcSEcCtD
Meloxicam—Anaphylactic shock—Prednisone—multiple sclerosis	6.83e-05	0.000589	CcSEcCtD
Meloxicam—Oedema—Prednisone—multiple sclerosis	6.83e-05	0.000589	CcSEcCtD
Meloxicam—Abdominal pain—Methylprednisolone—multiple sclerosis	6.81e-05	0.000588	CcSEcCtD
Meloxicam—Decreased appetite—Betamethasone—multiple sclerosis	6.81e-05	0.000588	CcSEcCtD
Meloxicam—Decreased appetite—Dexamethasone—multiple sclerosis	6.81e-05	0.000588	CcSEcCtD
Meloxicam—Nausea—Mitoxantrone—multiple sclerosis	6.8e-05	0.000587	CcSEcCtD
Meloxicam—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	6.79e-05	0.00522	CbGpPWpGaD
Meloxicam—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	6.79e-05	0.00522	CbGpPWpGaD
Meloxicam—Infection—Prednisone—multiple sclerosis	6.78e-05	0.000585	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	6.77e-05	0.000584	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Betamethasone—multiple sclerosis	6.77e-05	0.000584	CcSEcCtD
Meloxicam—Back pain—Methotrexate—multiple sclerosis	6.76e-05	0.000584	CcSEcCtD
Meloxicam—Fatigue—Betamethasone—multiple sclerosis	6.76e-05	0.000583	CcSEcCtD
Meloxicam—Fatigue—Dexamethasone—multiple sclerosis	6.76e-05	0.000583	CcSEcCtD
Meloxicam—Shock—Prednisone—multiple sclerosis	6.72e-05	0.00058	CcSEcCtD
Meloxicam—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	6.72e-05	0.00517	CbGpPWpGaD
Meloxicam—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	6.72e-05	0.00517	CbGpPWpGaD
Meloxicam—Pain—Betamethasone—multiple sclerosis	6.7e-05	0.000579	CcSEcCtD
Meloxicam—Pain—Dexamethasone—multiple sclerosis	6.7e-05	0.000579	CcSEcCtD
Meloxicam—Nervous system disorder—Prednisone—multiple sclerosis	6.7e-05	0.000578	CcSEcCtD
Meloxicam—Tachycardia—Prednisone—multiple sclerosis	6.66e-05	0.000575	CcSEcCtD
Meloxicam—Skin disorder—Prednisone—multiple sclerosis	6.63e-05	0.000572	CcSEcCtD
Meloxicam—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	6.62e-05	0.0051	CbGpPWpGaD
Meloxicam—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	6.62e-05	0.0051	CbGpPWpGaD
Meloxicam—Hyperhidrosis—Prednisone—multiple sclerosis	6.6e-05	0.00057	CcSEcCtD
Meloxicam—Vision blurred—Methotrexate—multiple sclerosis	6.59e-05	0.000569	CcSEcCtD
Meloxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	6.54e-05	0.00503	CbGpPWpGaD
Meloxicam—Ill-defined disorder—Methotrexate—multiple sclerosis	6.49e-05	0.00056	CcSEcCtD
Meloxicam—Anaemia—Methotrexate—multiple sclerosis	6.46e-05	0.000558	CcSEcCtD
Meloxicam—Feeling abnormal—Dexamethasone—multiple sclerosis	6.46e-05	0.000558	CcSEcCtD
Meloxicam—Feeling abnormal—Betamethasone—multiple sclerosis	6.46e-05	0.000558	CcSEcCtD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—multiple sclerosis	6.42e-05	0.00494	CbGpPWpGaD
Meloxicam—Gastrointestinal pain—Dexamethasone—multiple sclerosis	6.41e-05	0.000553	CcSEcCtD
Meloxicam—Gastrointestinal pain—Betamethasone—multiple sclerosis	6.41e-05	0.000553	CcSEcCtD
Meloxicam—Hypersensitivity—Triamcinolone—multiple sclerosis	6.37e-05	0.000549	CcSEcCtD
Meloxicam—Hypersensitivity—Methylprednisolone—multiple sclerosis	6.35e-05	0.000548	CcSEcCtD
Meloxicam—PGD—Metabolism—CYP27B1—multiple sclerosis	6.34e-05	0.00488	CbGpPWpGaD
Meloxicam—PGD—Metabolism—CYP24A1—multiple sclerosis	6.34e-05	0.00488	CbGpPWpGaD
Meloxicam—Malaise—Methotrexate—multiple sclerosis	6.3e-05	0.000544	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—multiple sclerosis	6.29e-05	0.00484	CbGpPWpGaD
Meloxicam—Vertigo—Methotrexate—multiple sclerosis	6.28e-05	0.000542	CcSEcCtD
Meloxicam—Leukopenia—Methotrexate—multiple sclerosis	6.26e-05	0.00054	CcSEcCtD
Meloxicam—Urticaria—Betamethasone—multiple sclerosis	6.23e-05	0.000537	CcSEcCtD
Meloxicam—Urticaria—Dexamethasone—multiple sclerosis	6.23e-05	0.000537	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Prednisone—multiple sclerosis	6.22e-05	0.000537	CcSEcCtD
Meloxicam—Dizziness—Prednisolone—multiple sclerosis	6.21e-05	0.000536	CcSEcCtD
Meloxicam—Asthenia—Triamcinolone—multiple sclerosis	6.2e-05	0.000535	CcSEcCtD
Meloxicam—Abdominal pain—Dexamethasone—multiple sclerosis	6.2e-05	0.000535	CcSEcCtD
Meloxicam—Abdominal pain—Betamethasone—multiple sclerosis	6.2e-05	0.000535	CcSEcCtD
Meloxicam—Body temperature increased—Dexamethasone—multiple sclerosis	6.2e-05	0.000535	CcSEcCtD
Meloxicam—Body temperature increased—Betamethasone—multiple sclerosis	6.2e-05	0.000535	CcSEcCtD
Meloxicam—Asthenia—Methylprednisolone—multiple sclerosis	6.19e-05	0.000534	CcSEcCtD
Meloxicam—Insomnia—Prednisone—multiple sclerosis	6.17e-05	0.000533	CcSEcCtD
Meloxicam—Paraesthesia—Prednisone—multiple sclerosis	6.13e-05	0.000529	CcSEcCtD
Meloxicam—PTGS2—S1P1 pathway—MAPK1—multiple sclerosis	6.12e-05	0.00471	CbGpPWpGaD
Meloxicam—Pruritus—Triamcinolone—multiple sclerosis	6.11e-05	0.000528	CcSEcCtD
Meloxicam—Cough—Methotrexate—multiple sclerosis	6.1e-05	0.000527	CcSEcCtD
Meloxicam—Pruritus—Methylprednisolone—multiple sclerosis	6.1e-05	0.000526	CcSEcCtD
Meloxicam—Convulsion—Methotrexate—multiple sclerosis	6.06e-05	0.000523	CcSEcCtD
Meloxicam—Dyspepsia—Prednisone—multiple sclerosis	6.01e-05	0.000519	CcSEcCtD
Meloxicam—Arthralgia—Methotrexate—multiple sclerosis	5.95e-05	0.000514	CcSEcCtD
Meloxicam—Myalgia—Methotrexate—multiple sclerosis	5.95e-05	0.000514	CcSEcCtD
Meloxicam—Decreased appetite—Prednisone—multiple sclerosis	5.93e-05	0.000512	CcSEcCtD
Meloxicam—Rash—Prednisolone—multiple sclerosis	5.92e-05	0.000511	CcSEcCtD
Meloxicam—PTGS1—Overview of nanoparticle effects—IL6—multiple sclerosis	5.92e-05	0.00456	CbGpPWpGaD
Meloxicam—Dermatitis—Prednisolone—multiple sclerosis	5.92e-05	0.000511	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	5.91e-05	0.00051	CcSEcCtD
Meloxicam—Diarrhoea—Methylprednisolone—multiple sclerosis	5.9e-05	0.000509	CcSEcCtD
Meloxicam—Fatigue—Prednisone—multiple sclerosis	5.89e-05	0.000508	CcSEcCtD
Meloxicam—Headache—Prednisolone—multiple sclerosis	5.89e-05	0.000508	CcSEcCtD
Meloxicam—Discomfort—Methotrexate—multiple sclerosis	5.88e-05	0.000508	CcSEcCtD
Meloxicam—Constipation—Prednisone—multiple sclerosis	5.84e-05	0.000504	CcSEcCtD
Meloxicam—PTGS2—Overview of nanoparticle effects—TNF—multiple sclerosis	5.83e-05	0.00448	CbGpPWpGaD
Meloxicam—PGD—Metabolism—GPC5—multiple sclerosis	5.8e-05	0.00446	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.8e-05	0.00446	CbGpPWpGaD
Meloxicam—Confusional state—Methotrexate—multiple sclerosis	5.75e-05	0.000497	CcSEcCtD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	5.75e-05	0.00443	CbGpPWpGaD
Meloxicam—Dizziness—Triamcinolone—multiple sclerosis	5.71e-05	0.000493	CcSEcCtD
Meloxicam—Anaphylactic shock—Methotrexate—multiple sclerosis	5.71e-05	0.000492	CcSEcCtD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—multiple sclerosis	5.7e-05	0.00439	CbGpPWpGaD
Meloxicam—Dizziness—Methylprednisolone—multiple sclerosis	5.7e-05	0.000492	CcSEcCtD
Meloxicam—Infection—Methotrexate—multiple sclerosis	5.67e-05	0.000489	CcSEcCtD
Meloxicam—Feeling abnormal—Prednisone—multiple sclerosis	5.63e-05	0.000486	CcSEcCtD
Meloxicam—Asthenia—Dexamethasone—multiple sclerosis	5.62e-05	0.000485	CcSEcCtD
Meloxicam—Asthenia—Betamethasone—multiple sclerosis	5.62e-05	0.000485	CcSEcCtD
Meloxicam—Nervous system disorder—Methotrexate—multiple sclerosis	5.6e-05	0.000483	CcSEcCtD
Meloxicam—Thrombocytopenia—Methotrexate—multiple sclerosis	5.59e-05	0.000482	CcSEcCtD
Meloxicam—ABCC4—Platelet degranulation—ALB—multiple sclerosis	5.58e-05	0.0043	CbGpPWpGaD
Meloxicam—Gastrointestinal pain—Prednisone—multiple sclerosis	5.58e-05	0.000482	CcSEcCtD
Meloxicam—Nausea—Prednisolone—multiple sclerosis	5.58e-05	0.000482	CcSEcCtD
Meloxicam—Pruritus—Betamethasone—multiple sclerosis	5.55e-05	0.000479	CcSEcCtD
Meloxicam—Pruritus—Dexamethasone—multiple sclerosis	5.55e-05	0.000479	CcSEcCtD
Meloxicam—Skin disorder—Methotrexate—multiple sclerosis	5.54e-05	0.000478	CcSEcCtD
Meloxicam—Hyperhidrosis—Methotrexate—multiple sclerosis	5.52e-05	0.000476	CcSEcCtD
Meloxicam—Vomiting—Triamcinolone—multiple sclerosis	5.49e-05	0.000474	CcSEcCtD
Meloxicam—PGD—NRF2 pathway—TGFB1—multiple sclerosis	5.48e-05	0.00422	CbGpPWpGaD
Meloxicam—Vomiting—Methylprednisolone—multiple sclerosis	5.48e-05	0.000473	CcSEcCtD
Meloxicam—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	5.47e-05	0.0042	CbGpPWpGaD
Meloxicam—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	5.47e-05	0.0042	CbGpPWpGaD
Meloxicam—Rash—Triamcinolone—multiple sclerosis	5.45e-05	0.00047	CcSEcCtD
Meloxicam—Dermatitis—Triamcinolone—multiple sclerosis	5.44e-05	0.00047	CcSEcCtD
Meloxicam—Rash—Methylprednisolone—multiple sclerosis	5.44e-05	0.000469	CcSEcCtD
Meloxicam—Dermatitis—Methylprednisolone—multiple sclerosis	5.43e-05	0.000469	CcSEcCtD
Meloxicam—Urticaria—Prednisone—multiple sclerosis	5.42e-05	0.000468	CcSEcCtD
Meloxicam—Headache—Triamcinolone—multiple sclerosis	5.41e-05	0.000467	CcSEcCtD
Meloxicam—Headache—Methylprednisolone—multiple sclerosis	5.4e-05	0.000466	CcSEcCtD
Meloxicam—Body temperature increased—Prednisone—multiple sclerosis	5.4e-05	0.000466	CcSEcCtD
Meloxicam—Abdominal pain—Prednisone—multiple sclerosis	5.4e-05	0.000466	CcSEcCtD
Meloxicam—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	5.39e-05	0.00415	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	5.39e-05	0.00415	CbGpPWpGaD
Meloxicam—Diarrhoea—Dexamethasone—multiple sclerosis	5.36e-05	0.000463	CcSEcCtD
Meloxicam—Diarrhoea—Betamethasone—multiple sclerosis	5.36e-05	0.000463	CcSEcCtD
Meloxicam—Hypotension—Methotrexate—multiple sclerosis	5.33e-05	0.00046	CcSEcCtD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—ALB—multiple sclerosis	5.32e-05	0.00409	CbGpPWpGaD
Meloxicam—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.2e-05	0.000449	CcSEcCtD
Meloxicam—Dizziness—Dexamethasone—multiple sclerosis	5.18e-05	0.000447	CcSEcCtD
Meloxicam—Dizziness—Betamethasone—multiple sclerosis	5.18e-05	0.000447	CcSEcCtD
Meloxicam—Insomnia—Methotrexate—multiple sclerosis	5.16e-05	0.000445	CcSEcCtD
Meloxicam—Nausea—Triamcinolone—multiple sclerosis	5.13e-05	0.000443	CcSEcCtD
Meloxicam—Paraesthesia—Methotrexate—multiple sclerosis	5.12e-05	0.000442	CcSEcCtD
Meloxicam—Nausea—Methylprednisolone—multiple sclerosis	5.12e-05	0.000442	CcSEcCtD
Meloxicam—Dyspnoea—Methotrexate—multiple sclerosis	5.09e-05	0.000439	CcSEcCtD
Meloxicam—ABCC4—Hemostasis—PLEK—multiple sclerosis	5.07e-05	0.0039	CbGpPWpGaD
Meloxicam—Somnolence—Methotrexate—multiple sclerosis	5.07e-05	0.000438	CcSEcCtD
Meloxicam—Hypersensitivity—Prednisone—multiple sclerosis	5.03e-05	0.000434	CcSEcCtD
Meloxicam—Dyspepsia—Methotrexate—multiple sclerosis	5.02e-05	0.000433	CcSEcCtD
Meloxicam—Vomiting—Dexamethasone—multiple sclerosis	4.98e-05	0.00043	CcSEcCtD
Meloxicam—Vomiting—Betamethasone—multiple sclerosis	4.98e-05	0.00043	CcSEcCtD
Meloxicam—PTGS2—Spinal Cord Injury—CCR2—multiple sclerosis	4.98e-05	0.00383	CbGpPWpGaD
Meloxicam—Decreased appetite—Methotrexate—multiple sclerosis	4.96e-05	0.000428	CcSEcCtD
Meloxicam—Rash—Betamethasone—multiple sclerosis	4.94e-05	0.000427	CcSEcCtD
Meloxicam—Rash—Dexamethasone—multiple sclerosis	4.94e-05	0.000427	CcSEcCtD
Meloxicam—Dermatitis—Dexamethasone—multiple sclerosis	4.94e-05	0.000426	CcSEcCtD
Meloxicam—Dermatitis—Betamethasone—multiple sclerosis	4.94e-05	0.000426	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Methotrexate—multiple sclerosis	4.93e-05	0.000425	CcSEcCtD
Meloxicam—Fatigue—Methotrexate—multiple sclerosis	4.92e-05	0.000425	CcSEcCtD
Meloxicam—Headache—Betamethasone—multiple sclerosis	4.91e-05	0.000424	CcSEcCtD
Meloxicam—Headache—Dexamethasone—multiple sclerosis	4.91e-05	0.000424	CcSEcCtD
Meloxicam—Asthenia—Prednisone—multiple sclerosis	4.9e-05	0.000423	CcSEcCtD
Meloxicam—Pain—Methotrexate—multiple sclerosis	4.88e-05	0.000421	CcSEcCtD
Meloxicam—Pruritus—Prednisone—multiple sclerosis	4.83e-05	0.000417	CcSEcCtD
Meloxicam—PGD—Metabolism—RRM1—multiple sclerosis	4.8e-05	0.0037	CbGpPWpGaD
Meloxicam—Feeling abnormal—Methotrexate—multiple sclerosis	4.7e-05	0.000406	CcSEcCtD
Meloxicam—PTGS2—Overview of nanoparticle effects—IL6—multiple sclerosis	4.7e-05	0.00362	CbGpPWpGaD
Meloxicam—Diarrhoea—Prednisone—multiple sclerosis	4.67e-05	0.000403	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.67e-05	0.000403	CcSEcCtD
Meloxicam—Nausea—Dexamethasone—multiple sclerosis	4.66e-05	0.000402	CcSEcCtD
Meloxicam—Nausea—Betamethasone—multiple sclerosis	4.66e-05	0.000402	CcSEcCtD
Meloxicam—Urticaria—Methotrexate—multiple sclerosis	4.53e-05	0.000391	CcSEcCtD
Meloxicam—Dizziness—Prednisone—multiple sclerosis	4.51e-05	0.00039	CcSEcCtD
Meloxicam—Body temperature increased—Methotrexate—multiple sclerosis	4.51e-05	0.000389	CcSEcCtD
Meloxicam—Abdominal pain—Methotrexate—multiple sclerosis	4.51e-05	0.000389	CcSEcCtD
Meloxicam—PGD—Disease—RPL5—multiple sclerosis	4.5e-05	0.00346	CbGpPWpGaD
Meloxicam—PTGS1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.4e-05	0.00339	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	4.39e-05	0.00338	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—ICAM1—multiple sclerosis	4.37e-05	0.00336	CbGpPWpGaD
Meloxicam—Vomiting—Prednisone—multiple sclerosis	4.34e-05	0.000375	CcSEcCtD
Meloxicam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	4.31e-05	0.00332	CbGpPWpGaD
Meloxicam—PGD—Disease—SLC11A1—multiple sclerosis	4.31e-05	0.00332	CbGpPWpGaD
Meloxicam—Rash—Prednisone—multiple sclerosis	4.3e-05	0.000372	CcSEcCtD
Meloxicam—Dermatitis—Prednisone—multiple sclerosis	4.3e-05	0.000371	CcSEcCtD
Meloxicam—Headache—Prednisone—multiple sclerosis	4.28e-05	0.000369	CcSEcCtD
Meloxicam—Hypersensitivity—Methotrexate—multiple sclerosis	4.2e-05	0.000363	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	4.15e-05	0.00319	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CXCL10—multiple sclerosis	4.14e-05	0.00319	CbGpPWpGaD
Meloxicam—Asthenia—Methotrexate—multiple sclerosis	4.09e-05	0.000353	CcSEcCtD
Meloxicam—Nausea—Prednisone—multiple sclerosis	4.06e-05	0.00035	CcSEcCtD
Meloxicam—Pruritus—Methotrexate—multiple sclerosis	4.04e-05	0.000348	CcSEcCtD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	3.99e-05	0.00307	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	3.99e-05	0.00307	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—CCL2—multiple sclerosis	3.91e-05	0.00301	CbGpPWpGaD
Meloxicam—Diarrhoea—Methotrexate—multiple sclerosis	3.9e-05	0.000337	CcSEcCtD
Meloxicam—ABCC4—Ectoderm Differentiation—CCL2—multiple sclerosis	3.87e-05	0.00298	CbGpPWpGaD
Meloxicam—Dizziness—Methotrexate—multiple sclerosis	3.77e-05	0.000326	CcSEcCtD
Meloxicam—PTGS2—Spinal Cord Injury—BDNF—multiple sclerosis	3.72e-05	0.00286	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	3.69e-05	0.00284	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—ALB—multiple sclerosis	3.64e-05	0.0028	CbGpPWpGaD
Meloxicam—Vomiting—Methotrexate—multiple sclerosis	3.63e-05	0.000313	CcSEcCtD
Meloxicam—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	3.6e-05	0.00277	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	3.6e-05	0.00277	CbGpPWpGaD
Meloxicam—Rash—Methotrexate—multiple sclerosis	3.6e-05	0.00031	CcSEcCtD
Meloxicam—Dermatitis—Methotrexate—multiple sclerosis	3.59e-05	0.00031	CcSEcCtD
Meloxicam—ABCC4—Hemostasis—SELE—multiple sclerosis	3.57e-05	0.00275	CbGpPWpGaD
Meloxicam—Headache—Methotrexate—multiple sclerosis	3.57e-05	0.000308	CcSEcCtD
Meloxicam—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	3.56e-05	0.00273	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	3.56e-05	0.00273	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—TGFB1—multiple sclerosis	3.53e-05	0.00272	CbGpPWpGaD
Meloxicam—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.51e-05	0.0027	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.47e-05	0.00267	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	3.47e-05	0.00267	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IL4—multiple sclerosis	3.45e-05	0.00266	CbGpPWpGaD
Meloxicam—PGD—Disease—CD28—multiple sclerosis	3.44e-05	0.00265	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	3.43e-05	0.00264	CbGpPWpGaD
Meloxicam—Nausea—Methotrexate—multiple sclerosis	3.39e-05	0.000292	CcSEcCtD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	3.36e-05	0.00259	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—IFNG—multiple sclerosis	3.33e-05	0.00256	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	3.17e-05	0.00244	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	3.17e-05	0.00244	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	3.15e-05	0.00242	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—CCL2—multiple sclerosis	3.11e-05	0.00239	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	3.08e-05	0.00237	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.07e-05	0.00236	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	3.02e-05	0.00232	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—IL1B—multiple sclerosis	2.97e-05	0.00228	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—ALB—multiple sclerosis	2.89e-05	0.00223	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	2.87e-05	0.00221	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TLR4—multiple sclerosis	2.86e-05	0.0022	CbGpPWpGaD
Meloxicam—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.86e-05	0.0022	CbGpPWpGaD
Meloxicam—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.84e-05	0.00219	CbGpPWpGaD
Meloxicam—PGD—Metabolism—BCHE—multiple sclerosis	2.76e-05	0.00212	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—ICAM1—multiple sclerosis	2.74e-05	0.00211	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	2.69e-05	0.00207	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	2.65e-05	0.00204	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	2.64e-05	0.00203	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—ITGA4—multiple sclerosis	2.58e-05	0.00199	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.58e-05	0.00198	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.58e-05	0.00198	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—IFNB1—multiple sclerosis	2.57e-05	0.00197	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	2.53e-05	0.00195	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—SRM—multiple sclerosis	2.52e-05	0.00194	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	2.48e-05	0.00191	CbGpPWpGaD
Meloxicam—PGD—Disease—CD86—multiple sclerosis	2.46e-05	0.00189	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	2.46e-05	0.00189	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	2.36e-05	0.00181	CbGpPWpGaD
Meloxicam—PTGS1—Biological oxidations—POMC—multiple sclerosis	2.34e-05	0.0018	CbGpPWpGaD
Meloxicam—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.31e-05	0.00178	CbGpPWpGaD
Meloxicam—ABCC4—Ectoderm Differentiation—MYC—multiple sclerosis	2.29e-05	0.00176	CbGpPWpGaD
Meloxicam—ABCC4—NRF2 pathway—TGFB1—multiple sclerosis	2.18e-05	0.00168	CbGpPWpGaD
Meloxicam—PGD—Disease—CCR5—multiple sclerosis	2.18e-05	0.00168	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	2.17e-05	0.00167	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—TNF—multiple sclerosis	2.15e-05	0.00166	CbGpPWpGaD
Meloxicam—PGD—Disease—HLA-A—multiple sclerosis	2.12e-05	0.00163	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.1e-05	0.00161	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.1e-05	0.00161	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	2.09e-05	0.00161	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	2.01e-05	0.00154	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—SRM—multiple sclerosis	2e-05	0.00154	CbGpPWpGaD
Meloxicam—PGD—Disease—APOE—multiple sclerosis	1.98e-05	0.00152	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	1.9e-05	0.00146	CbGpPWpGaD
Meloxicam—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.88e-05	0.00145	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	1.86e-05	0.00143	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	1.86e-05	0.00143	CbGpPWpGaD
Meloxicam—PGD—Disease—CD80—multiple sclerosis	1.79e-05	0.00138	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CYP27B1—multiple sclerosis	1.78e-05	0.00137	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CYP24A1—multiple sclerosis	1.78e-05	0.00137	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—IL2RA—multiple sclerosis	1.77e-05	0.00136	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	1.76e-05	0.00135	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.74e-05	0.00134	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—IL6—multiple sclerosis	1.74e-05	0.00134	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	1.71e-05	0.00131	CbGpPWpGaD
Meloxicam—PGD—Metabolism—APOE—multiple sclerosis	1.66e-05	0.00128	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—SRM—multiple sclerosis	1.63e-05	0.00125	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GPC5—multiple sclerosis	1.63e-05	0.00125	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.57e-05	0.00121	CbGpPWpGaD
Meloxicam—PTGS2—Disease—GPC5—multiple sclerosis	1.54e-05	0.00119	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.54e-05	0.00118	CbGpPWpGaD
Meloxicam—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.53e-05	0.00117	CbGpPWpGaD
Meloxicam—PGD—Disease—TYK2—multiple sclerosis	1.51e-05	0.00116	CbGpPWpGaD
Meloxicam—CYP2C8—Biological oxidations—POMC—multiple sclerosis	1.51e-05	0.00116	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	1.45e-05	0.00112	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	1.45e-05	0.00111	CbGpPWpGaD
Meloxicam—PGD—Metabolism—POMC—multiple sclerosis	1.43e-05	0.0011	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	1.42e-05	0.00109	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP27B1—multiple sclerosis	1.41e-05	0.00109	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP24A1—multiple sclerosis	1.41e-05	0.00109	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.38e-05	0.00106	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	1.38e-05	0.00106	CbGpPWpGaD
Meloxicam—PGD—Disease—CD4—multiple sclerosis	1.37e-05	0.00105	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	1.35e-05	0.00104	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—RRM1—multiple sclerosis	1.35e-05	0.00104	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—SRM—multiple sclerosis	1.33e-05	0.00102	CbGpPWpGaD
Meloxicam—PGD—Metabolism—ALB—multiple sclerosis	1.3e-05	0.001	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GPC5—multiple sclerosis	1.29e-05	0.000993	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—ALB—multiple sclerosis	1.28e-05	0.000982	CbGpPWpGaD
Meloxicam—CYP2C9—Biological oxidations—POMC—multiple sclerosis	1.23e-05	0.000946	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	1.15e-05	0.000884	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	1.15e-05	0.000884	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.12e-05	0.000864	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.11e-05	0.00085	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	1.09e-05	0.000839	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—RRM1—multiple sclerosis	1.07e-05	0.000823	CbGpPWpGaD
Meloxicam—PGD—Disease—STAT3—multiple sclerosis	1.06e-05	0.000815	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GPC5—multiple sclerosis	1.05e-05	0.000808	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.05e-05	0.000804	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—IL2—multiple sclerosis	1.04e-05	0.000796	CbGpPWpGaD
Meloxicam—PTGS2—Disease—RPL5—multiple sclerosis	1e-05	0.000771	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	9.87e-06	0.000759	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	9.85e-06	0.000757	CbGpPWpGaD
Meloxicam—PGD—Disease—MYC—multiple sclerosis	9.84e-06	0.000757	CbGpPWpGaD
Meloxicam—PGD—Disease—TGFB1—multiple sclerosis	9.82e-06	0.000755	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	9.66e-06	0.000743	CbGpPWpGaD
Meloxicam—PGD—Disease—MAPK1—multiple sclerosis	9.63e-06	0.000741	CbGpPWpGaD
Meloxicam—PTGS2—Disease—SLC11A1—multiple sclerosis	9.6e-06	0.000739	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	9.35e-06	0.000719	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	9.35e-06	0.000719	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	9.19e-06	0.000707	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	9.14e-06	0.000703	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.98e-06	0.000691	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SRM—multiple sclerosis	8.75e-06	0.000673	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—RRM1—multiple sclerosis	8.7e-06	0.00067	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GPC5—multiple sclerosis	8.55e-06	0.000658	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.3e-06	0.000638	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.19e-06	0.00063	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—POMC—multiple sclerosis	8.11e-06	0.000624	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—TGFB1—multiple sclerosis	8.07e-06	0.000621	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—MAPK1—multiple sclerosis	7.92e-06	0.000609	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—BCHE—multiple sclerosis	7.74e-06	0.000595	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CD28—multiple sclerosis	7.67e-06	0.00059	CbGpPWpGaD
Meloxicam—PGD—Disease—IL6—multiple sclerosis	7.4e-06	0.000569	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.13e-06	0.000548	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—RRM1—multiple sclerosis	7.08e-06	0.000545	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.75e-06	0.000519	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.5e-06	0.0005	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	6.16e-06	0.000474	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	6.16e-06	0.000474	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—BCHE—multiple sclerosis	6.14e-06	0.000473	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.8e-06	0.000446	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GPC5—multiple sclerosis	5.64e-06	0.000434	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.5e-06	0.000423	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CD86—multiple sclerosis	5.47e-06	0.000421	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.29e-06	0.000407	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—BCHE—multiple sclerosis	5e-06	0.000385	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CCR5—multiple sclerosis	4.85e-06	0.000373	CbGpPWpGaD
Meloxicam—PTGS2—Disease—HLA-A—multiple sclerosis	4.73e-06	0.000364	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.72e-06	0.000363	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—RRM1—multiple sclerosis	4.67e-06	0.000359	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—APOE—multiple sclerosis	4.66e-06	0.000358	CbGpPWpGaD
Meloxicam—PTGS2—Disease—APOE—multiple sclerosis	4.41e-06	0.00034	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.3e-06	0.000331	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—BCHE—multiple sclerosis	4.07e-06	0.000313	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—POMC—multiple sclerosis	4e-06	0.000308	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CD80—multiple sclerosis	3.99e-06	0.000307	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—APOE—multiple sclerosis	3.7e-06	0.000284	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—ALB—multiple sclerosis	3.65e-06	0.000281	CbGpPWpGaD
Meloxicam—PTGS2—Disease—TYK2—multiple sclerosis	3.37e-06	0.000259	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—POMC—multiple sclerosis	3.18e-06	0.000244	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CD4—multiple sclerosis	3.05e-06	0.000234	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—APOE—multiple sclerosis	3.01e-06	0.000231	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—ALB—multiple sclerosis	2.89e-06	0.000223	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.68e-06	0.000206	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—POMC—multiple sclerosis	2.58e-06	0.000199	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—APOE—multiple sclerosis	2.45e-06	0.000188	CbGpPWpGaD
Meloxicam—PTGS2—Disease—STAT3—multiple sclerosis	2.36e-06	0.000181	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—ALB—multiple sclerosis	2.36e-06	0.000181	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MYC—multiple sclerosis	2.19e-06	0.000169	CbGpPWpGaD
Meloxicam—PTGS2—Disease—TGFB1—multiple sclerosis	2.19e-06	0.000168	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MAPK1—multiple sclerosis	2.14e-06	0.000165	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—POMC—multiple sclerosis	2.1e-06	0.000162	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—ALB—multiple sclerosis	1.92e-06	0.000147	CbGpPWpGaD
Meloxicam—PTGS2—Disease—IL6—multiple sclerosis	1.65e-06	0.000127	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—APOE—multiple sclerosis	1.61e-06	0.000124	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—POMC—multiple sclerosis	1.39e-06	0.000107	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ALB—multiple sclerosis	1.26e-06	9.73e-05	CbGpPWpGaD
